Join

Compare · DMPI vs DRNA

DMPI vs DRNA

Side-by-side comparison of DelMar Pharmaceuticals, Inc. (DMPI) and Dicerna Pharmaceuticals, Inc. (DRNA): market cap, price performance, sector, and recent activity on the wire.

Summary

  • Both DMPI and DRNA operate in Major Pharmaceuticals (Health Care), so they compete in similar markets.
  • DRNA carries a market cap of $2.96B.
  • DRNA has more recent analyst coverage (14 ratings vs 0 for DMPI).
MetricDMPIDRNA
Company
DelMar Pharmaceuticals, Inc.
Dicerna Pharmaceuticals, Inc.
Price
-
$38.23+0.61%
Market cap
-
$2.96B
1M return
-
-
1Y return
-
-
Sector
Health Care
Health Care
Industry
Major Pharmaceuticals
Major Pharmaceuticals
Exchange
NASDAQ
NASDAQ
IPO
n/a
2014
News (4w)
0
0
Recent ratings
0
14
DRNA

Dicerna Pharmaceuticals, Inc.

Dicerna Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercializing of ribonucleic acid interference (RNAi)-based pharmaceuticals. The company develops pharmaceuticals using its GalXC RNAi platform for the treatment of diseases involving the liver, including rare, cardiometabolic, viral, and chronic liver diseases; complement-mediated diseases; and neurodegenerative diseases and pain. Its principal development programs include nedosiran for the treatment of primary hyperoxaluria; RG6346 for the treatment of chronic hepatitis B virus infection; belcesiran for the treatment of deficiency-associated liver disease; and DCR-AUD for the treatment of alcohol use disorder. Dicerna Pharmaceuticals, Inc. has strategic collaborations with Novo Nordisk A/S, F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc., Eli Lilly and Company, Alnylam Pharmaceuticals, Inc., Alexion Pharmaceuticals, Inc., and Boehringer Ingelheim International GmbH. The company was incorporated in 2006 and is headquartered in Lexington, Massachusetts.

Latest DMPI

No recent items for DelMar Pharmaceuticals, Inc..

Latest DRNA